Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Fendrix vs Engerix-B in Dialysis Patients
NCT00383591Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2002
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, open-label trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: Anti-HBs seroprotection rate at Month 36 and Anamnestic response to booster dose at Month 42. Started Mar 2002; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00383591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383591.